Next Article in Journal
Adjuvant Chemoradiation for Gastric Cancer with Infusional 5-Fluorouracil and Cisplatin: A Phase I Study
Previous Article in Journal
Ductal Carcinoma In Situ in a 25-Year-Old Man Presenting with Apparent Unilateral Gynecomastia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 17
Issue 4
10.3747/co.v17i4.700
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality

by
Su. Verma
1,2,*,
S. Lavasani
2,
J. Mackey
3,
K. Pritchard
1,2,
M. Clemons
4,
S. Dent
4,5,
J. Latreille
6,
J. Lemieux
7,
L. Provencher
8,
Sh. Verma
4,5,
S. Chia
9,
B. Wang
10 and
D. Rayson
11
1
University of Toronto, Toronto, ON, Canada
2
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
3
Division of Medical Oncology, Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada
4
Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
5
University of Ottawa, Ottawa, ON
6
Centre Intégré de cancérologie de la Montérégie, Université de Sherbrooke, and Réseau Cancer Montérégie, Longueuil, QC, Canada
7
Unité de recherche en santé des populations, Centre de Recherche du Centre Hospitalier affilié universitaire de Québec, Quebec City, QC, Canada
8
Hôpital du Saint-Sacrement, Quebec City, QC, Canada
9
British Columbia Breast Tumour Group, British Columbia Cancer Agency–Vancouver Centre, Vancouver, BC, Canada
10
Remedy Communications, Toronto, ON, Canada
11
Atlantic Clinical Cancer Research Unit (ACCRU) and QEII Cancer Care Program, QEII Health Sciences Centre, Halifax, NS, Canada
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2010, 17(4), 20-33; https://doi.org/10.3747/co.v17i4.700
Submission received: 9 May 2010 / Revised: 7 June 2010 / Accepted: 9 July 2010 / Published: 1 August 2010

Abstract

Breast cancer positive for HER2 (human epidermal growth factor receptor 2) is associated with a poor prognosis for patients with both early-stage and metastatic breast cancer. Trastuzumab has been shown to be effective and is now considered the standard of care for early-stage patients with HER2-positive breast cancer. In that population, trastuzumab has been studied in six randomized clinical trials. Overall, use of this agent leads to a significant reduction in risk of disease recurrence and improvement in overall survival. Despite the strong evidence for the use of trastuzumab in managing HER2-positive early breast cancer (EBC), a number of clinical controversies remain. The authors of this paper undertook a review of the available scientific literature on adjuvant trastuzumab to produce practical considerations from Canadian oncologists. The panel focused their discussion on five key areas: (1) Management of node-negative disease with tumours 1 cm or smaller in size; (2) Management of HER2-positive EBC across the spectrum of the disease (that is, nodal and steroid hormone receptor status, tumour size); (3) Timing of trastuzumab therapy with chemotherapy for early-stage disease: concurrent or sequential; (4) Treatment duration of trastuzumab for EBC; (5) The role of non-anthracycline trastuzumab-based regimens.
Keywords: adjuvant; early breast cancer; her2-positive; node-negative; trastuzumab adjuvant; early breast cancer; her2-positive; node-negative; trastuzumab

Share and Cite

MDPI and ACS Style

Verma, S.; Lavasani, S.; Mackey, J.; Pritchard, K.; Clemons, M.; Dent, S.; Latreille, J.; Lemieux, J.; Provencher, L.; Verma, S.; et al. Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality. Curr. Oncol. 2010, 17, 20-33. https://doi.org/10.3747/co.v17i4.700

AMA Style

Verma S, Lavasani S, Mackey J, Pritchard K, Clemons M, Dent S, Latreille J, Lemieux J, Provencher L, Verma S, et al. Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality. Current Oncology. 2010; 17(4):20-33. https://doi.org/10.3747/co.v17i4.700

Chicago/Turabian Style

Verma, Su., S. Lavasani, J. Mackey, K. Pritchard, M. Clemons, S. Dent, J. Latreille, J. Lemieux, L. Provencher, Sh. Verma, and et al. 2010. "Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality" Current Oncology 17, no. 4: 20-33. https://doi.org/10.3747/co.v17i4.700

APA Style

Verma, S., Lavasani, S., Mackey, J., Pritchard, K., Clemons, M., Dent, S., Latreille, J., Lemieux, J., Provencher, L., Verma, S., Chia, S., Wang, B., & Rayson, D. (2010). Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality. Current Oncology, 17(4), 20-33. https://doi.org/10.3747/co.v17i4.700

Article Metrics

Back to TopTop